Invest in Ipca Laboratories, says Kunj Bansal

Kunj Bansal of Centrum Wealth Management told CNBC-TV18, "In pharma sector because of the new pricing policy there were a lot of issues and then there was a dispute with trade. So, to that extent there was some concern that the domestic sales would come down which doesn’t seem to have happened.”

He further added, “There are opportunities at current levels of prices also. Ipca Laboratories which has moved up after its results but has come down from the peak again, so at current level of Rs 810 odd we think is a good investment opportunity.”

“Aurobindo Pharma has been having a significant movement but the conviction after their results is coming back. The price has marginally corrected, so that is positive. Although if it corrects more it will be additional conviction.”